Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML) | Aplastic Anemia & MDS International Foundation
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML)

Clinical Trial: NCT02807272

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with Acute Myeloid Leukemia (AML). Subjects (amendment 3 Cohorts 1-4) will receive tipifarnib administered at a dose of 400 mg, orally with food, twice a day (bid) for 21 days in 28 day cycles.

Status: 
Recruiting
Study Date: 
Mon, 10/03/2016 to Tue, 05/31/2022
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • chronic myelomonocytic leukaemia (CMML)
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)
Intervention: 
Drug: Tipifarnib Oral tablet Other Names: R115777 Zarnestra